Alaunos Therapeutics, Inc.

NasdaqCM:TCRT Voorraadrapport

Marktkapitalisatie: US$3.8m

Alaunos Therapeutics Beheer

Beheer criteriumcontroles 3/4

De CEO Alaunos Therapeutics is Dale Hogue, benoemd in Jan2024, heeft een ambtstermijn van minder dan een jaar. bezit rechtstreeks 0.25% van de aandelen van het bedrijf, ter waarde $ 9.56K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 3.9 jaar.

Belangrijke informatie

Dale Hogue

Algemeen directeur

US$11.1k

Totale compensatie

Percentage CEO-salarisn/a
Dienstverband CEOless than a year
Eigendom CEO0.2%
Management gemiddelde ambtstermijn3yrs
Gemiddelde ambtstermijn bestuur3.9yrs

Recente managementupdates

Recent updates

Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Nov 10
Health Check: How Prudently Does Alaunos Therapeutics (NASDAQ:TCRT) Use Debt?

Alaunos wins bullish view at Wells Fargo on promise of cell therapy technology

Oct 04

Alaunos posts 51% tumor reduction for lung cancer therapy

Sep 21

Alaunos sheds 52% ahead of data readout for T-cell therapy platform

Sep 15

Alaunos Therapeutics: Keep An Eye On Upcoming TCR-T Solid Tumor Study Data

Aug 31

Alaunos Therapeutics GAAP EPS of -$0.05 beats by $0.02

Aug 15

Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Jul 26
Is Alaunos Therapeutics (NASDAQ:TCRT) Weighed On By Its Debt Load?

Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Apr 06
Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt Sensibly?

Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Dec 20
Is ZIOPHARM Oncology (NASDAQ:ZIOP) A Risky Investment?

Ziopharm: Waiting On FYE 2021 For Further Clinical Data On TCR-T/CAR-T Therapies

Jun 19

ZIOPHARM records sharpest gain in nearly four months

Jun 09

Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

May 11
Will ZIOPHARM Oncology (NASDAQ:ZIOP) Spend Its Cash Wisely?

ZIOPHARM Oncology, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

Mar 09
How Much Of ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP) Do Institutions Own?

We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

Jan 15
We're Hopeful That ZIOPHARM Oncology (NASDAQ:ZIOP) Will Use Its Cash Wisely

ZioPharm highlights upcoming catalysts, says current cash runway into mid-2022

Jan 14

Ziopharm Oncology to test non-viral CAR-T in leukemia and lymphoma patients

Dec 21

Activist holder wins Ziopharm Oncology board seats

Dec 17

Ziopharm Oncology CFO to step down

Dec 14

What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Nov 23
What Is The Ownership Structure Like For ZIOPHARM Oncology, Inc. (NASDAQ:ZIOP)?

Ziopharm says WaterMill’s nominees lack experience, White Rock backs proposal on board reconstitution

Nov 20

ZIOPHARM Oncology, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 06

Ziopharm Oncology thumbs down on investor's call for board seats

Nov 02

CEO

Dale Hogue (54 yo)

less than a year

Tenure

US$11,090

Compensatie

Mr. Dale Curtis Hogue, Jr. is Director of Alaunos Therapeutics, Inc. from December 29, 2023 and also serves as Interim Chief Executive Officer from January 20, 2024. Mr. Hogue has worked in various roles...


Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Dale Hogue
Interim CEO & Directorless than a yearUS$11.09k0.25%
$ 9.6k
Melinda Lackey
Senior VP of Legal3yrsUS$701.74kgeen gegevens
Michael Wong
Vice President of Finance & Principal Accounting Officer3.2yrsgeen gegevensgeen gegevens

3.0yrs

Gemiddelde duur

47yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van TCRT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).


Bestuursleden

NaamPositieTenureCompensatieEigendom
Dale Hogue
Interim CEO & Directorless than a yearUS$11.09k0.25%
$ 9.6k
Holger Weis
Independent Chairman of the Board3.9yrsUS$900.26k0.076%
$ 2.9k
Carl June
Chairman of Scientific Advisory Board4.4yrsgeen gegevensgeen gegevens
Jaime Vieser
Independent Director3.9yrsUS$103.26k0.97%
$ 37.0k
Matthew Porteus
Member of Scientific Advisory Board4.2yrsgeen gegevensgeen gegevens
Kole Roybal
Member of Scientific Advisory Board4.2yrsgeen gegevensgeen gegevens
Robert Hofmeister
Independent Director1.7yrsUS$84.01k0%
$ 0
Robert Postma
Independent Director3.8yrsUS$104.26k0.52%
$ 19.8k
Steven Feldman
Member of Scientific Advisory Boardno datageen gegevensgeen gegevens

3.9yrs

Gemiddelde duur

58yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van TCRT wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).